Nouvelles approches thérapeutiques dans les leucémies aiguës lymphoblastiques

The emergence of targeted therapies has drastically improved the outcome of some ALL sub-types. Patients presenting Philadelphia chromosome ALL, nowadays, receive chemotherapy and Tyrosine Kinase Inhibitors as first line treatment, this combination, not only, improves the CR rates but also limits treatment related toxicity. Targeted therapies already have many applications, as their use is less toxic, it enables to treat older patients who represent a growing number of patients, and because their mechanism of action is different from chemotherapy, they offer new hopes for patients presenting refractory ALL.